EUVIMEDEUVIMED entdecken
Fallbericht

How I diagnose Erdheim-Chester disease

Aishwarya Ravindran, Karen L Rech, Histio-Care Network

American Journal of Clinical Pathology · 04.08.2026 · 166 (2)

DOI: 10.1093/ajcp/aqag094 ↗

Kurz gefasst

Fallbericht in der Zeitschrift American Journal of Clinical Pathology, online erschienen am 21.08.2026. Verfasst von Aishwarya Ravindran und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States. Hauptthemen laut MEDLINE: Erdheim-Chester Disease. Die Arbeit nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Erdheim-Chester disease (ECD) is one of 3 major types of histiocytic neoplasms, along with Rosai-Dorfman disease and Langerhans cell histiocytosis. It was first recognized as a neoplasm in the 2016 World Health Organization Classification of Haematolymphoid Tumours. About 80% to 90% of cases harbor MAPK pathway mutations.

Methods

We discuss the diagnosis of ECD using 3 illustrative cases, consider interpretative challenges, and present a diagnostic algorithm.

Results

Erdheim-Chester disease is a systemic disease that shows a characteristic pattern of organ involvement including bone, perinephric soft tissue, skin, heart, and central nervous system. Histologically, ECD shows a spectrum of xanthogranulomatous, lymphohistocytic, or fibrohistiocytic infiltrates. By immunohistochemistry, the neoplastic histiocytes have a macrophage phenotype with expression of CD163, negative to focal S100, and negative CD1a and langerin. These features alone are not specific and thus insufficient for diagnosis. Immunohistochemistry for cyclin D1 and BRAF V600E, correlation with clinical and imaging findings, and mutational analysis for MAPK pathway mutations all play important roles in establishing an ECD diagnosis.

Conclusions

The diagnosis of ECD is often challenging due to its clinical and histologic overlap with reactive inflammatory processes. Correlation of histology features with clinical findings, immunohistochemistry, and genetic studies is essential for an accurate and timely diagnosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erdheim-Chester DiseaseAdultHumansMaleHistiocytesImmunohistochemistryMutationAged

Stichwörter der Autor:innen

ECDMAPK/ERKnon-LCH

Autor:innen und Institutionen

  • Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States.

Zitieren

APA

Ravindran, A., Rech, K. L., & Histio-Care Network (2026). How I diagnose Erdheim-Chester disease. American Journal of Clinical Pathology, 166(2). https://doi.org/10.1093/ajcp/aqag094

Vancouver

Ravindran A, Rech KL, Histio-Care Network. How I diagnose Erdheim-Chester disease. American Journal of Clinical Pathology. 2026;166(2). doi:10.1093/ajcp/aqag094

BibTeX
@article{Ravindran2026,
  author = {Ravindran, Aishwarya and Rech, Karen L and Histio-Care Network, Histio-Care Network},
  title = {How I diagnose Erdheim-Chester disease},
  journal = {American Journal of Clinical Pathology},
  year = {2026},
  volume = {166},
  number = {2},
  doi = {10.1093/ajcp/aqag094}
}
Kostenlos starten →